Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adebrelimab + chemotherapy + apatinib first-line for advanced pulmonary neuroendocrine tumors
ChiCTR2400094718Phase 2Recruiting
- Sponsor
- Beijing Chest Hospital
- Start
- Dec 2024
- Modality
- Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of adebrelimab, Rivoceranib, etoposide, carboplatin and cisplatin in bronchial neuroendocrine tumor, small cell lung cancer (SCLC), large cell neuroendocrine carcinoma (LCNEC) and 1 more, sponsored by Beijing Chest Hospital. Primary endpoint: 12-month progression-free survival rate. Started Dec 2024; status: recruiting.
02
Drugs
adebrelimabRivoceranibetoposidecarboplatincisplatin
03
Conditions
bronchial neuroendocrine tumorsmall cell lung cancer (SCLC)large cell neuroendocrine carcinoma (LCNEC)Bronchopulmonary Carcinoid (BPC)
Beyond the preview
Go deeper on ChiCTR2400094718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094718.